Robbins LLP Informs Investors of ImmunityBio Class Action Lawsuit

Law firm notifies investors of pending lawsuit against biotech company ImmunityBio.

Mar. 27, 2026 at 12:50am

Got story updates? Submit your updates here. ›

The law firm Robbins LLP has informed investors of a class action lawsuit filed against ImmunityBio, Inc., a biotechnology company. The lawsuit alleges that ImmunityBio made false and misleading statements about its business, operations, and prospects, which resulted in investors suffering significant losses.

Why it matters

This lawsuit is significant for ImmunityBio investors, as it could potentially lead to financial compensation if the allegations are proven true. The outcome of the case could also impact the company's reputation and future business prospects.

The details

The class action lawsuit was filed in the U.S. District Court for the Southern District of California on behalf of investors who purchased ImmunityBio securities between January 1, 2025, and December 31, 2025. The lawsuit alleges that ImmunityBio made false and misleading statements about the progress and success of its clinical trials, as well as the company's financial condition and future prospects.

  • The class action lawsuit was filed on March 26, 2026.
  • The lawsuit covers the period from January 1, 2025, to December 31, 2025.

The players

Robbins LLP

A law firm that specializes in shareholder rights and securities litigation, and has informed investors of the class action lawsuit against ImmunityBio.

ImmunityBio, Inc.

A biotechnology company that is the subject of the class action lawsuit, which alleges the company made false and misleading statements about its business, operations, and prospects.

Got photos? Submit your photos here. ›

What’s next

The judge will determine whether the class action lawsuit against ImmunityBio can proceed as a class action, which would allow more investors to join the case.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosure for publicly traded companies, as investors rely on this information to make informed decisions. The outcome of the case could have significant implications for ImmunityBio and its investors.